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a  b  s  t  r  a  c  t
Background  and purpose:  It  remains  undetermined  whether  the addition  of  ezetimibe  to  ongoing  statin
therapy  is  more  effective  than  increasing  the  dose  of  statin  for  reducing  remnant  lipoprotein  levels  in
patients  with  remnant  lipoproteinemia  on  previous  statin  treatment.  This  study  examined  whether  com-
bined  ezetimibe  and  statin  therapy  resulted  in  a greater  improvement  in remnant  lipoprotein  levels  and
endothelial  function  than  with  the  dose  of  statin  in patients  with  remnant  lipoproteinemia  on  previous
statin  treatment.
Methods and results:  A  total  of  63  patients  with  stable  coronary  artery  disease  and  high levels  of  remnant-
like  lipoprotein  particle  cholesterol  (RLP-C)  (≥5.0  mg/dL)  on  statin  treatment  were  assigned  randomly
to  two  groups  and  treated  with  either  addition  of  ezetimibe  (10  mg/day,  n = 32)  or doubling  of statin
dose  (n  =  31).  The  lipid proﬁles  and  ﬂow-mediated  dilation  (FMD)  of  the  brachial  artery  were  measured
at  enrollment  and  after  6 months  of  treatment.  Statin  and  ezetimibe  combined  therapy  reduced  RLP-C
and  improved  FMD  to a  greater  extent  than  doubling  the  statin  dose  (%  reduction  in RLP-C, 48  ± 18%  vs.
33  ±  24%,  respectively,  p  = 0.01;  % improvement  in  FMD,  47  ±  48%  vs.  24 ± 23%,  respectively,  p  = 0.02).
Conclusions:  The  addition  of ezetimibe  to ongoing  statin  treatment  reduced  RLP-C  levels  and  improved
endothelial  dysfunction  to a  greater  extent  than  doubling  the statin  dose  in  patients  with high  RLP-C
levels  on previous  statin  treatment.  The  present  results  are  preliminary  and  should  be conﬁrmed  by
further  studies  on a larger  number  of  study  patients.
©  2012  Japanese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.ntroduction
High levels of remnant lipoprotein, triglyceride (TG)-rich
ipoprotein are atherogenic and a major risk factor for cardio-
ascular diseases [1–5]. Remnant lipoproteinemia in combination
ith high levels of low-density lipoprotein cholesterol (LDL-C)
s a feature of hyperlipidemia in patients with type 2 diabetes
ellitus (DM) or the metabolic syndrome [3–5]. Statins are the
rst-line lipid-lowering drug for these patients with combined
yperlipidemia [6,7]. The US National Cholesterol Education Pro-
ram guidelines recommend reducing LDL-C levels to <100 mg/dL
ith statin treatment in high-risk patients [7].  However, many
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oi:10.1016/j.jjcc.2012.02.005patients fail to achieve their LDL-C goals with statin treatment due
to either a failure to titrate their dosages adequately or poor patient
compliance [8].  In addition, statins are not successful in reducing
remnant lipoprotein levels in some patients with remnant lipopro-
teinemia [9].  An increase in statin dose or combination with other
lipid-lowering drugs is therefore required to treat these patients
with resistant hyperlipidemia.
Ezetimibe is a hypocholesterolemic drug that acts by selec-
tively inhibiting intestinal cholesterol absorption [10,11]. There
is evidence that the addition of ezetimibe to statin therapy pro-
vides signiﬁcant additional improvements in lipid proﬁle and
LDL-C goal attainment [12–16].  Although several previous reports
showed that ezetimibe lowered TG-rich lipoproteins [17–19],  it
remains undetermined whether addition of ezetimibe to ongoing
statin therapy is more effective than increasing statin dosage for
reducing remnant lipoprotein levels. Endothelial vasomotor dys-
function has been identiﬁed as an early event in the pathogenesis
of atherosclerosis and a surrogate marker of future cardiovascular
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vents [20,21]. We  have shown previously that lipid-lowering ther-
pies improved endothelial vasomotor dysfunction in patients with
emnant lipoproteinemia [22]. The current study therefore exam-
ned whether ezetimibe added to ongoing statin therapy resulted in
reater improvement in lipid proﬁles and endothelial function than
oubling the statin dose in patients with remnant lipoproteinemia
n previous statin treatment.
ethods
tudy patients
All the patients gave written, informed consent for the study at
nrollment. The study was conducted in accordance with the guide-
ines approved by the ethics committee of Yamanashi University
ospital. The investigation conformed to the principles outlined
n the 1975 Declaration of Helsinki. This study was carried out
t the cardiology section of Yamanashi University Hospital and
nvolved screening 210 patients with stable coronary artery dis-
ase (CAD) who had been taking a stable daily dose of a statin for
he previous 3 months and had shown good compliance. All of these
atients with stable CAD had no episodes of angina at rest and no
hanges in the frequency of angina in the previous year. The inclu-
ion criteria were as follows: (1) remnant-like lipoprotein particle
holesterol (RLP-C) levels ≥5.0 mg  and LDL-C levels ≥100 mg/dL
t screening; (2) aged 35–75 years; and (3) angiographic docu-
entation of an organic stenosis of ≥75% of ≥1 major coronary
rtery. Patients were included if there was a signiﬁcant stenosis
reviously but the stenosis was reduced to ≤50% after coronary
evascularization. The exclusion criteria were as follows: (1) taking
ipid-altering agents other than statins during the 6 weeks prior
o screening; (2) taking thiazolidinediones, -adrenergic agonists,
r glucocorticoids; (3) acute coronary syndromes or stroke in the
revious 4 weeks; (4) New York Heart Association class III or IV
ongestive heart failure; (5) major surgery and trauma or serious
nfectious diseases in the previous 4 weeks; (6) impaired renal
unction (serum creatinine ≥ 2.0 mg/dL), active liver disease, statin-
nduced myopathy, uncontrolled diabetes mellitus (hemoglobin
1c ≥ 9%), or untreated hypothyroidism or hyperthyroidism; and
7) any medical condition that the investigator determined could
imit a patient’s evaluation or participation. The study ﬁnally
nrolled 63 patients who met  the inclusion and exclusion criteria.
ll the patients were ethnic Japanese.
tudy protocol
All the study patients were randomly assigned, using random
umbers generated by a computer, into two treatment groups to
eceive either ezetimibe 10 mg/day plus their prescribed statin
herapy and dose (statin–ezetimibe group, n = 32) or doubling of
heir ongoing statin dose (double-dose statin group, n = 31). After
his assignment, the prescribed statin and dose were maintained
hroughout the study. All patients were instructed to continue
he same medications except for ezetimibe, healthy lifestyle
hanges including exercise and dietary recommendations includ-
ng a cholesterol-lowering diet, throughout the study, that they
eceived before the enrollment to this study. The addition of lipid-
owering medications other than the assigned statin and ezetimibe
as prohibited during the study period. Measurement of ﬂow-
ediated vasodilation (FMD) of the brachial artery and blood
ampling was carried out on the same morning at enrollment
fter an overnight fast. The tests were repeated after 6 months.
atients were withdrawn from the study if they experienced any
dverse events during the follow-up period, including a persistent
ncrease (2 consecutive measurements) in alanine transaminaserdiology 60 (2012) 12–17 13
(ALT) and aspartate transaminase (AST) levels to ≥2 times the upper
limit of normal; persistent increase in creatine phosphokinase (CK)
levels to ≥3 times the upper limit of normal, associated with mus-
cular symptoms; unexplained CK elevation 5 or more times the
upper limit of normal, without muscle symptoms; drug eruption;
or occurrence of serious diseases. The prescribed statin and other
medications taken by the study patients are shown in Table 1.
The primary efﬁcacy variables were the percentage change in
RLP-C from baseline after 6 months of treatment and the number of
patients who achieved an RLP-C level <5.0 mg/dL. This target level
of RLP-C was determined arbitrarily on the basis of our previous
reports [2–4,9].  Secondary efﬁcacy variables were the percentage
change in LDL-C levels, number of patients achieving an LDL-C
level <100 mg/dL, and changes from baseline in FMD  of the brachial
artery after 6 months of treatment.
Measurements of FMD in the brachial artery
Vasodilator responses in the brachial arteries were measured
using B-mode ultrasound images and a 7.5-MHz linear array trans-
ducer (HP-5500, Phillips Corp., Tokyo, Japan) as described in our
previous studies [21,22]. Brieﬂy, optimal brachial artery images
were obtained between 1 and 5 cm above the antecubital crease.
This location was marked, and all subsequent images were obtained
at the same location. The exact distance from the measured point
on the skin surface to the antecubital crease was  recorded in each
subject to ensure that the same segment of the brachial artery
was measured at each time point during follow-up. The responses
of the vessel diameter and blood ﬂow to reactive hyperemia and
nitroglycerin were expressed as percentage increases in diameter
and blood ﬂow from the baseline value, respectively. In our stud-
ies, repeated measurements of baseline arterial diameter had an
inter-observer variability of 0.04 ± 0.01 mm and an intra-observer
variability of 0.02 ± 0.01 mm.  When these studies were performed
at the same time on 2 separate days in 20 control subjects, the
difference in arterial diameter during reactive hyperemia between
the 2 days in each subject was  0.05 ± 0.01 mm,  yielding a mean dif-
ference of 1.1 ± 1.0% in FMD. The investigators (M.H., K.W.) were
blinded to the treatment allocation throughout the study.
Laboratory examinations and measurement of carotid
intima-media thickness
Venous blood samples were obtained from all the patients after
a 12-h overnight fast at the same time point after vascular ultra-
sound assessment. Remnant-like lipoprotein particles (RLP) were
isolated by applying fasting serum to an immunoafﬁnity mixed gel
that contained anti-apoA-1 and anti-apoB-100 monoclonal anti-
bodies (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) using the
method described in our previous reports [2–4,9,22]. Serum insulin
levels were determined using an enzyme immunoassay (Tosoh,
Tokyo, Japan). High sensitivity C-reactive protein (CRP) levels were
assayed by rate nephelometry (Dade Behring, Marburg, Germany).
Serum total cholesterol and TG concentrations were measured
enzymatically, while serum high-density lipoprotein cholesterol
(HDL-C) concentration was measured by heparin-Ca2+/Ni2+ pre-
cipitation. LDL-C levels were calculated by the Friedewald formula
and non-HDL-C as total cholesterol minus HDL-C. The intima-media
thickness (IMT) of the carotid artery was measured using the same
method as per our previous report [3].
Statistical analysesData are expressed as the mean value ± SD, median and inter-
quartile range (25 and 75th percentiles) or frequencies (%). The
mean values and frequencies in the two groups were compared
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Table  1
Comparisons of baseline clinical characteristics.
Doubling statin dose (n = 28) Statin + ezetimibe (n = 29) p-Value
Age (years) 64 ± 9.2 61 ± 10.0 0.32
Gender (male) 23 (82.1) 22 (75.9) 0.56
History of ACS 20 (71.4) 23 (79.3) 0.49
Hypertension 17 (60.7) 18 (62.1) 0.92
Current smoking 12 (42.9) 15 (51.7) 0.50
Diabetes mellitus 10 (37.0) 10 (34.5) 0.84
Total  cholesterol (mg/dL) 200 (187, 221) 193 (182, 221) 0.94
Triglyceride (mg/dL) 175 (156, 182) 173 (149, 179) 0.80
HDL-C (mg/dL) 44 ± 8.5 43 ± 10.0 0.71
LDL-C (mg/dL) 121 (107, 141) 120 (105, 139) 0.84
Non-HDL-C (mg/dL) 151 (141, 156) 152 (143, 157) 0.96
RLP-C (mg/dL) 6.5 (5.4, 8.6) 6.6 (5.6, 9.2) 0.88
Fasting glucose (mg/dL) 103 ± 22.7 112 ± 28.0 0.18
Fasting IRI (mg/dL) 9.4 ± 4.1 8.2 ± 4.3 0.30
BMI  (kg/m2) 25.2 ± 3.1 24.6 ± 3.0 0.45
CRP  (g/dL) 0.08 (0.05, 0.35) 0.10 (0.04, 0.28) 0.60
Ultrasound parameters
Maximum IMT  (mm) 1.8 ± 0.6 1.9 ± 0.6 0.40
FMD  (%) 5.4 ± 4.1 5.5 ± 7.1 0.46
Statin therapy
Atorvastatin 6 (21.4) 2 (6.9) 0.11
Pravastatin 12 (42.9) 17 (58.6) 0.23
Rosuvastatin 9 (32.1) 7 (24.1) 0.50
Pitavastatin 1 (3.6) 3 (10.3) 0.32
Other medication
Aspirin 29 (100) 32 (100) –
Clopidogrel 27 (96.4) 27 (93.1) 0.57
Beta  blocker 12 (42.9) 6 (20.7) 0.07
ACEI/ARB 14 (51.9) 14 (48.3) 0.79
Diuretics 3 (10.7) 4 (13.8) 0.72
Values are expressed as the mean value ± SD, median and inter-quartile range (25 and 75th percentiles) or number (%) of patients. ACS, acute coronary syndrome; HDL-C,






























tody  mass index; CRP, C-reactive protein; IMT, intima-media thickness; FMD, ﬂow
eceptor blocker.
sing Student’s unpaired t test and Chi-square analysis, respec-
ively. The Shapiro–Wilk test showed that the levels of total
holesterol, TG, LDL-C, non-HDL-C, RLP-C and CRP levels were
ot distributed normally, and therefore these data were log-
ransformed for statistical analysis. The mean value of lipids, other
iochemical parameters, and FMD  indices at enrollment (baseline)
nd after 6 months of treatment were compared between the 2
roups using two-way analysis of variance for repeated measures,
ollowed by post hoc testing. The relationship of % changes in FMD
rom baseline to 24 weeks of treatment with % changes in clinical
arameters from both treatment groups was assessed using uni-
ariate linear regression analysis or nonparametric Spearman rank
orrelation test. The independent relationships of % changes in FMD
ith % changes in clinical parameters were assessed by multivari-
te linear regression analysis using % changes in clinical parameters
rom both treatment groups as covariates that were signiﬁcantly
elated with % changes in FMD  using univariate linear regression
nalysis or nonparametric Spearman rank correlation test. All prob-
bility values presented are two-tailed, with statistical signiﬁcance
eing inferred at p < 0.05. The statistical analyses were carried out
sing mainly STATA 10.0 (StataCorp, College Station, TX, USA) and
lso IBM SPSS Statistics 18.0 (SPSS Japan Inc., Tokyo, Japan).
esults
omparisons of baseline clinical parameters of the study patients
The clinical characteristics, prescribed statin, and FMD at base-
ine were similar between the statin–ezetimibe group and double-
ose statin group (Table 1). The baseline dose of each prescribed
tatin before the enrollment was not statistically different between
he statin–ezetimibe group and the double-dose statin groupted dilatation; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II
(atorvastatin, 10 ± 0 mg/day vs. 11.7 ± 2.6 mg/day, respectively;
pravastatin, 12.7 ± 3.2 mg/day vs. 13.8 ± 4.8 mg/day, respectively;
rosuvastatin 5.8 ± 2.2 mg/day vs. 6.1 ± 1.9 mg/day, respectively;
pitavastatin, 1.5 ± 0.5 mg/day vs. 2 ± 0 mg/day, respectively).
Effects of treatments on clinical parameters
During the study, 3 patients were withdrawn from the
statin–ezetimibe group due to a stroke (1 patient), skin eruption (1),
and an increase in ALT/AST (1), while 3 patients were withdrawn
from the double-dose statin group due to an increase in CK (1)
and ALT/AST (2). The effects of the treatments on lipid parameters
and FMD  are shown in Table 2. Both treatment groups had signif-
icant reductions in total cholesterol, TG, LDL-C, non-HDL-C, RLP-C,
and CRP levels. The double-dose statin group showed a signiﬁcant
increase in HDL-C levels, whereas the statin–ezetimibe group did
not. The % reduction in CRP levels was greater in the double-dose
statin group than the statin–ezetimibe group. The % reduction in
RLP-C levels was  greater in the statin–ezetimibe group compared
to the double-dose statin group. Similarly, the number of patients
achieving an RLP-C level <5.0 mg/dL was  signiﬁcantly higher in the
statin–ezetimibe group than the double-dose statin group (n = 24
[83%] vs. n = 16 [57%], respectively, p = 0.02). The % reduction in
LDL-C levels also tended to be greater in the statin–ezetimibe
group than in the double-dose statin group, although this dif-
ference was  not statistically signiﬁcant. The rate of achieving an
LDL-C level <100 mg/dL was  not signiﬁcantly different between the
statin–ezetimibe group and the double-dose statin group (n = 22
[76%] vs. n = 17 [61%], respectively, p = 0.22). The % reduction in
total cholesterol, TG, and non-HDL-C levels were also similar in
the two groups. Systolic blood pressure, fasting glucose levels, and
IMT  of the carotid artery were not signiﬁcantly changed after either
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Table  2
Changes in lipids and FMD  after 6 months of treatment.
Doubling statin dose (n = 28) Statin + ezetimibe (n = 29) p-Value
Total cholesterol (mg/dL)
Baseline 200 (187, 221) 193 (182, 221) 0.94
6  months 175 (160, 189)* 165 (148, 176)* 0.15
%  change from baseline −13.9 ± 13.0 −19.2 ± 10.4 0.09
Triglyceride (mg/dL)
Baseline 175 (156, 182) 173 (149, 179) 0.80
6  months 143 (116, 184)* 137 (109, 184)* 0.67
%  change from baseline −20.9 ± 18.7 −24.2 ± 23.2 0.56
HDL-C (mg/dL)
Baseline 44 ± 8.5 43 ± 10.0 0.71
6  months 48 ± 8.3* 44 ± 8.0 0.08
%  change from baseline 11.2 ± 19.7 5.0 ± 15.2 0.18
LDL-C  (mg/dL)
Baseline 121 (107, 141) 120 (105, 139) 0.84
6  months 96 (86, 111)* 92 (79, 105)* 0.40
%  change from baseline −20.3 ± 18.3 −23.8 ± 15.7 0.14
Non-HDL-C (mg/dL)
Baseline 151 (141, 156) 152 (143, 157) 0.96
6  months 124 (112, 140)* 120 (105, 127)* 0.37
%  change from baseline −20.1 ± 15.6 −24.8 ± 13.1 0.22
RLP-C  (mg/dL)
Baseline 6.5 (5.4, 8.6) 6.6 (5.6, 9.2) 0.88
6  months 4.4 (3.3, 5.5)* 4.1 (2.9, 4.5)* 0.14
%  change from baseline −33.4 ± 24.4 −47.8 ± 18.3 0.01
CRP  (mg/L)
Baseline 0.08 (0.05, 0.35) 0.10 (0.04, 0.28) 0.60
6  months 0.03 (0.01, 0.08)* 0.05 (0.02, 0.12)* 0.04
%  change from baseline −59.5 ± 30.0 −42.7 ± 33.0 0.04
Maximum IMT (mm)
Baseline 1.8 ± 0.6 1.9 ± 0.6 0.40
6  months 1.8 ± 0.6 1.9 ± 0.6 0.89
%  change from baseline 0.4 ± 8.4 1.0 ± 8.4 0.80
FMD  (%)
Baseline 5.4 ± 4.1 5.5 ± 7.1 0.46
6  months 6.7 ± 5.9* 8.1 ± 9.7* 0.13
%  change from baseline 24 ± 23.1 47 ± 47.5 0.02
Systolic blood pressure (mmHg)
Baseline 135 ± 12 132 ± 17 0.56
6  months 135 ± 8 131 ± 12 0.21
%  change from baseline 0.6 ± 7.5 −0.1 ± 13.1 0.54
Fasting glucose (mg/dL)
Baseline 104 ± 22.2 106 ± 16.7 0.63
6  months 105 ± 22.9 107 ± 25.0 0.68




















cMD, ﬂow mediated dilatation; HDL-C, high-density lipoprotein cholesterol; LDL-C, 
RP,  C-reactive protein; IMT, intima-media thickness.
* p < 0.05 vs. baseline values.
reatment (Table 2). No patient changed smoking status during the
tudy period in either treatment group.
ffects of treatment on FMD
FMD  improved signiﬁcantly in both groups, although the %
mprovement in FMD  was greater in the statin–ezetimibe group
han in the double-dose statin group. Dilator responses of the
rachial arteries to nitroglycerin did not change signiﬁcantly dur-
ng the study in either group (data not shown). In univariate linear
egression analysis or non-parametric Spearman rank correlation
est, the % improvement in FMD  was associated with % changes
n TG ( = −0.22, p = 0.04), non-HDL-C ( = −0.30, p = 0.03), RLP-
 ( = −0.38, p = 0.01), and CRP levels ( = −0.40, p = 0.01) among
he changes in clinical parameters listed in Table 2, including
oth treatment groups. Multivariate linear regression analysis
howed that the % improvement in FMD  correlated signiﬁcantly
ith the % change in RLP-C levels, with this relationship being
ndependent of % changes in TG, non-HDL, and CRP levels as
ovariates from both treatment groups (standardized regression
oefﬁcient = −0.48, p = 0.01).ensity lipoprotein cholesterol; RLP-C, remnant-like lipoprotein particle cholesterol;
Discussion
The present study showed that the addition of ezetimibe to
statin therapy caused a greater reduction in RLP-C levels than dou-
bling the statin dosage. In addition, combined statin–ezetimibe
therapy resulted in a greater improvement in FMD  compared
to increasing the statin dose. This indicates that the addition of
ezetimibe is associated with beneﬁcial changes in both remnant
lipoprotein levels and endothelial function in patients with rem-
nant lipoproteinemia on previous statin treatment. However, this
study included only a relatively small number of patients, which
limited the statistical power of the analyses to show small differ-
ences between the two  groups. And, the brand and dose of statin
varied among the patients, although the level of these variabilities
was similar between the two  treatment groups. Thus, the present
results are preliminary and should be conﬁrmed by further com-
parative studies that have same brand and dose of statin prescribed
at baseline in a larger number of study patients. Moreover, if only
strong statins such as atorvastatin or rosuvastatin with higher doses
were used in the present study, there is a possibility that the double
dose of statin group may  have a greater reduction in RLP-C lev-
els and a greater improvement in FMD  than the statin–ezetimibe
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roup. However, a recent randomized crossover study showed
hat combination therapy with atorvastatin (10 mg/day) and eze-
imibe (10 mg/day) reduced RLP-C levels to a greater extent than
onotherapy with atorvastatin (20 mg/day) [23].
Ezetimibe has been shown to have potential for reducing
G-rich lipoproteins by decreasing the cholesterol content of
hylomicrons and also by lowering cholesterol availability for
ery low-density lipoprotein (VLDL) [10]. Therefore, reducing
holesterol absorption with ezetimibe and decreasing cholesterol
ynthesis with statins provide complementary mechanisms for
educing the levels of TG-rich lipoproteins [10]. Several studies
ave demonstrated that ezetimibe administered with a statin pro-
ides additional improvements by lowering TG-rich lipoproteins
nd LDL-C levels over that of statins alone [18,19]. It has also
een shown that the superior lipid-lowering effects of ezetim-
be and statin combined therapy compared to statin monotherapy
re consistent when analyzed according to either statin brand or
ose [13,16].  The complementary mechanisms of ezetimibe and
tatin may  account for the greater decrease in RLP-C levels that
e observed with combined therapy compared to increasing the
tatin dose in the present study. We  have shown previously that
LP-C increased the susceptibility of the coronary endothelium to
xidative stress, leading to inhibition of nitric oxide-mediated arte-
ial dilation [24]. The present study showed a correlation between
he reduction in RLP-C levels and improvement in FMD. This rela-
ionship may  explain the greater improvement in FMD  that we
bserved in patients treated with combined therapy. The present
tudy showed that addition of ezetimibe reduced CRP levels in
he statin–ezetimibe group, which is in agreement with previous
eports [13,14,16,25]. However, the present study showed that the
eduction in CRP levels was greater in the double dose of statin
roup than the statin–ezetimibe group. This may  be explained by
 dose effect of statins on CRP levels [16]. The anti-inﬂammatory
ction of either ezetimibe or statin could contribute to the improve-
ent in FMD  in both treatment groups, but the anti-inﬂammatory
ction was unlikely to play a dominant role in the improvement in
MD  in the present study.
Although our study and previous studies have shown that
he combination of ezetimibe and statin is more effective for
educing atherogenic lipoprotein levels than statin monotherapy
12–16,18,19], it remains to be determined whether the combi-
ation also results in a greater reduction in future cardiovascular
vents than statin monotherapy. The present study demonstrated
hat FMD, a surrogate of future cardiovascular events, improved
o a greater extent with combined therapy than with doubling
he statin dose in patients with remnant lipoproteinemia. The
ddition of ezetimibe to ongoing statin therapy may  therefore
otentially improve clinical outcomes more favorably compared
ith an increasing dose of ongoing statin in patients with remnant
ipoproteinemia. However, the ENHANCE study in patients with
amilial hypercholesterolemia failed to demonstrate that addition
f ezetimibe to simvastatin reduced the progression of carotid
MT, another surrogate of future events, compared with simvas-
atin alone [25]. Also, the present study showed no signiﬁcant
ffect of addition of ezetimibe to statin on carotid IMT. In previ-
us studies [26–28],  the addition of ezetimibe to a statin improved
ndothelial function, although the superiority of combined therapy
n endothelial function was inconsistent and appeared to depend
n the statin dose, baseline lipid proﬁles, and extent of LDL-C
eduction. The IMPROVE-IT study, which is currently ongoing, will
etermine whether the addition of ezetimibe to statin therapy
simvastatin) improves cardiovascular outcomes compared with
tatin monotherapy in patients after ACS [29].
A number of previous studies showed that ezetimibe, either
lone or in combination with statin, effectively lowered TG-rich
ipoproteins including RLP-C [18–20].  However, only a few studiesrdiology 60 (2012) 12–17
have compared the ability of combined statin and ezetimibe ther-
apy with increasing the dose of statin to reduce remnant lipoprotein
levels. The present study is the ﬁrst to show that statin–ezetimibe
combined therapy caused a greater reduction in RLP-C levels than
doubling the statin dose in patients with remnant lipoproteine-
mia  on previous statin treatment. We  have shown previously that
high RLP-C levels are an important target for residual risk reduction
after statin therapy [2].  In this regard, the addition of ezetimibe to
ongoing statin therapy may  be recommended for reducing RLP-C
levels to target levels in patients with high RLP-C levels resistant to
previous statin therapy. The drug-related adverse events requiring
withdrawal from the study occurred in 2 of the 31 patients (6.5%)
in the statin–ezetimibe group and in 3 of the 31 patients (9.7%)
in the double-dose statin group. These results are consistent with
previous reports [12–17,19,20,30] and are in accordance with the
expectations for these drugs at the doses administered.
In conclusion, the addition of ezetimibe to ongoing statin ther-
apy reduced RLP-C levels and improved endothelial dysfunction
to a greater extent than doubling the statin dose in patients with
high RLP-C levels. However, the present results are preliminary and
should be conﬁrmed by further studies on a larger number of study
patients.
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